SciSparc Ltd.

Healthcare · Biotechnology · Israel

Last price 0.6763 USD (Oct 30, 2026, 4:00 PM EDT) · Market cap 392.91K

Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports

SciSparc Ltd., a clinical-stage pharmaceutical company, develops drugs based on cannabinoid therapies. Its drug development programs include SCI-110 for the treatment of Tourette syndrome and Alzheimer’s disease and agitation; SCI-210 for the treatment of autism spectrum disorder and status epilepticus; and CannAmide, an anti-inflammatory and chronic pain solution. The company sells hemp seed oil-based products and others. The company has an agreement with Procaps to develop and commercially manufacture SCI-110 and palmitoylethanolamide oral ta...